11 December 2017Big Pharma

UK government announces life sciences deal; GSK and AstraZeneca invest

The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UK govt invests in ‘world's largest’ genetics research project

12 September 2019 The world's ”largest genetics project” to tackle deadly diseases was launched yesterday, September 11, supported by funding from the UK government, charities and four pharmaceutical companies.

Big Pharma

UK life sciences partnership to use AI in disease detection

5 December 2018 The UK government and the life sciences industry have partnered to develop new technology using artificial intelligence to detect diseases at an early stage.

Europe

Regeneron forms consortium to fund exome sequencing

12 January 2018 Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

UK government announces life sciences deal; GSK and AstraZeneca invest

More on this story

Editor's picks

Editor's picks

More features